FDA clears Haemonetics' cell-washing capabilities:
This article was originally published in Clinica
Executive Summary
The US FDA has given Haemonetics' approval to broaden the use of its ACP 215 blood processing system to include a protocol for red blood cell washing. Previously cleared for freezing and thawing of red cells, the system can now allow doctors to remove more than 99% of plasma proteins from red blood cells derived from whole blood in a fully automated, closed system that supports good manufacturing practices, says the Braintree, Massachusetts firm. Plasma proteins can increase adverse patient reactions. The ACP 215 system reduces the labour involved with traditional red cell washing methods.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.